Trilogy Technologies’ blood glucose and cholesterol device @ CES 2024

Non-invasive blood glucose monitoring is a new technology designed to simplify and enhance the convenience of monitoring blood glucose levels for individuals with diabetes. Trilogy Technologies, a company specializing in non-invasive medical devices, has developed a device that not only detects blood glucose levels but also measures uric acid and total cholesterol levels. This device provides a painless and convenient method for individuals with diabetes to monitor their blood glucose levels, a significant improvement over traditional methods that require finger pricking. Non-invasive blood glucose monitoring This device is considered a game changer in the market as it eliminates the need for traditional methods such as drawing blood and testing it in certified labs. Pre-clinical trials have been conducted on the device, and it has demonstrated an accuracy rate of 93.49% compared to the golden standard. The device is compact and user-friendly, requiring no needles or jabs, thus offering a painless experience. To use the device, it is simply pressed against the skin and held lightly. Within 40 seconds, the device displays the blood glucose, uric acid, and total cholesterol levels. The values can also be streamed to Android phones or iPhones for easy tracking and monitoring. The device stands out for its simplicity. It is a one-time purchase with no need for a subscription. It is rechargeable, allowing for easy and ready use. An accompanying app provides data analysis, assisting users in tracking their health and promoting self-care. One of the key advantages of this non-invasive blood glucose monitoring device is its affordability. As it does not require expensive patches or continuous supplies, individuals can purchase the device and use it for an extended period of time. Furthermore, all the analysis is done within the device itself, eliminating the need for data to be sent to the cloud, thereby ensuring privacy and avoiding potential risks. Bringing the product to market and beyond The device has been well-received, with many seeing it as a potential solution to the increasing prevalence of chronic diseases, particularly diabetes. It is believed that this device could benefit millions of people, reducing the pain and frustration of monitoring blood glucose levels. It allows people with diabetes and other issues to check their levels anywhere at any time without risk of pain or contamination. Currently, Trilogy Technologies is conducting clinical trials to obtain FDA approval for their device. This step is crucial to ensure the device meets the required standards for accuracy and safety. It is expected that the device will be available for consumers in the third or fourth quarter of the year. Trilogy Technologies has expressed hope for widespread support of the product. The company’s goal is to enhance human health and encourage individuals to take responsibility for their own well-being. A release date in 2024 is being targeted. Conclusion: Trilogy Technologies is fixing blood glucose monitoring In conclusion, this innovative device, the non-invasive blood glucose monitor developed by Trilogy Technologies, has the potential to significantly improve personal health, especially for individuals with diabetes. Its simplicity, affordability, and potential to revolutionize blood glucose monitoring could have a significant impact on personal health and well-being. To learn more about the company, its products, and the future of the product, check out